Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,125.50DKK
5:56am EDT
Change (% chg)

kr.-2.00 (-0.18%)
Prev Close
kr.1,127.50
Open
kr.1,130.00
Day's High
kr.1,133.00
Day's Low
kr.1,119.50
Volume
34,374
Avg. Vol
236,598
52-wk High
kr.1,474.00
52-wk Low
kr.880.80

Chart for

About

Genmab A/S is a Denmark-based biotechnology company. It is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as relapsing remitting multiple sclerosis. Its product pipeline includes a number of research and development projects in... (more)

Overall

Beta: 1.29
Market Cap(Mil.): kr.68,820.71
Shares Outstanding(Mil.): 61.44
Dividend: --
Yield (%): --

Financials

  GEN.CO Industry Sector
P/E (TTM): 54.50 213.33 32.89
EPS (TTM): 20.69 -- --
ROI: 22.31 -3.69 13.14
ROE: 22.31 -5.73 15.15

Danish biotech Genmab hit by ending of trial using key cancer drug

COPENHAGEN Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug.

May 28 2018

Danish biotech Genmab hit by ending of trial using key cancer drug

COPENHAGEN, May 28 Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug.

May 28 2018

BRIEF-Genmab: Q1 Net Sales Of Darzalex At $432 Mln

* REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018

Apr 17 2018

Biotech group Genmab aims to own bigger share of new drug pipeline

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early-stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.

Apr 10 2018

BRIEF-Genmab ‍2017 Operating Profit Beats Expectations

* ‍PROJECTED REVENUE FOR 2018 CONSISTS PRIMARILY OF DARZALEX ROYALTIES OF APPROXIMATELY DKK 1,750 MLN THAT ARE BASED ON AN ESTIMATED USD 2.0 - 2.3 BLN OF DARZALEX NET SALES IN 2018​

Feb 21 2018

BRIEF-Genmab 2017 Net Sales Of DARZALEX At $1.24 Billion

* ANNOUNCES 2017 NET SALES FIGURES FOR DARZALEX® (DARATUMUMAB)

Jan 23 2018

BRIEF-Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​

* ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS

Jan 22 2018

BRIEF-U.S. FDA Grants Priority Review For Daratumumab In Front Line Multiple Myeloma

* U.S. FDA GRANTS PRIORITY REVIEW FOR DARATUMUMAB IN FRONT LINE MULTIPLE MYELOMA

Jan 19 2018

Earnings vs. Estimates